Payment overview · 2025
General Payments
$765.60
31 reported records · 17 companies
Healthcare provider profile · identity verified
Pedram Taher, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · WALNUT CREEK, CA · NPI 1669625125
Verified facts
What the public records show
CMS Open Payments records show Pedram Taher, M.D received $765.60 in general payments during 2025 across 31 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Paxlovid, Xifaxan.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $137.71 | 18.0% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $84.41 | 11.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.04 | 9.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $64.95 | 8.5% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $58.39 | 7.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.33 | 6.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $47.74 | 6.2% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $42.68 | 5.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.93 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.58 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.14 | 3.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.13 | 3.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.44 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.33 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.77 | 2.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.15 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.88 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $765.60 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $137.71 | 6 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $84.41 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.04 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $64.95 | 3 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $58.39 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.33 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $50.33 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $47.74 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $42.68 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 23 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
295 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 660 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 79 |
| Gabapentin | Gabapentin | 335 | 69 |
| Furosemide | Furosemide | 307 | 56 |
| Eliquis | Apixaban | 295 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 232 | 45 |
| Losartan Potassium | Losartan Potassium | 214 | 68 |
| Levetiracetam | Levetiracetam | 208 | 28 |
| Metformin Hcl | Metformin Hcl | 193 | 50 |
| Potassium Chloride | Potassium Chloride | 186 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 41 |
| Enoxaparin Sodium | Enoxaparin Sodium | 153 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 149 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 30 |
| Lisinopril | Lisinopril | 146 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 39 |
| Famotidine | Famotidine | 136 | 26 |
| Omeprazole | Omeprazole | 124 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 38 |
| Baclofen | Baclofen | 115 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 22 |
| Lorazepam | Lorazepam | 113 | 32 |
| Mirtazapine | Mirtazapine | 107 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 107 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 24 |
| Carvedilol | Carvedilol | 103 | 24 |
| Heparin Sodium | Heparin Sodium,porcine | 93 | suppressed |
| Jardiance | Empagliflozin | 92 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 24 |
| Glycopyrrolate | Glycopyrrolate | 89 | 13 |
| Donepezil Hcl | Donepezil Hcl | 84 | 20 |
| Trazodone Hcl | Trazodone Hcl | 84 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 28 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 71 | 23 |
| Cephalexin | Cephalexin | 69 | 33 |
| Xarelto | Rivaroxaban | 69 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 17 |
| Sertraline Hcl | Sertraline Hcl | 66 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 64 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 22 |
| Alendronate Sodium | Alendronate Sodium | 60 | 17 |
| Finasteride | Finasteride | 60 | 22 |
| Ezetimibe | Ezetimibe | 59 | 21 |
| Simvastatin | Simvastatin | 59 | 18 |
| Risperidone | Risperidone | 55 | suppressed |
| Memantine Hcl | Memantine Hcl | 54 | 12 |
| Allopurinol | Allopurinol | 53 | 19 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 19 |
| Tramadol Hcl | Tramadol Hcl | 50 | 13 |
| Lactulose | Lactulose | 49 | 13 |
| Midodrine Hcl | Midodrine Hcl | 49 | 11 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Atenolol | Atenolol | 44 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Sucralfate | Sucralfate | 42 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 41 | suppressed |
| Glipizide | Glipizide | 40 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Prednisone | Prednisone | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 12 |
| Erythromycin | Erythromycin Base | 34 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | 13 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 31 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | 12 |
| Humalog | Insulin Lispro | 27 | suppressed |
| Nystatin | Nystatin | 27 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Latanoprost | Latanoprost | 25 | 11 |
| Temazepam | Temazepam | 25 | suppressed |
| Xifaxan | Rifaximin | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Levemir | Insulin Detemir | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Humulin R | Insulin Regular, Human | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Methadone Hcl | Methadone Hcl | 20 | suppressed |
| Oxycontin | Oxycodone Hcl | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | 11 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Acetic Acid | Acetic Acid | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Corlanor | Ivabradine Hcl | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Effer-K | Potassium Bicarbonate/Cit Ac | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Riluzole | Riluzole | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $765.60 · 31 records | Otsuka America Pharmaceutical, Inc. | Auvelity, Belbuca, CAPLYTA, Dexcom G6 Transmitter, EVENITY, Fintepla, JARDIANCE, Kerendia, Leqembi, NURTEC ODT, PAXLOVID, REXULTI, SHINGRIX, Senza, The Cologuard Plus Collection Kit, XIFAXAN, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error